LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSanidad

2.63 -5.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.6

Máximo

2.71

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+657.58% upside

Dividendos
By Dow Jones
Próximas Ganancias	9 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-113M 276M
Apertura anterior	8.03
Cierre anterior	2.63

Noticias sobre sentimiento de mercado

By Acuity

50%

154 / 344 Clasificación en Healthcare

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 jun 2026, 23:22 UTC

Ganancias

Principales Movimientos del Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 jun 2026, 23:09 UTC

Acciones populares

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 jun 2026, 20:51 UTC

Ganancias

Costco Reports 15% Sales Growth in May

3 jun 2026, 20:43 UTC

Ganancias

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 jun 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 jun 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 jun 2026, 23:35 UTC

Charlas de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 jun 2026, 23:15 UTC

Charlas de Mercado

Ganancias

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 jun 2026, 22:08 UTC

Acciones populares

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 jun 2026, 21:54 UTC

Charlas de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 jun 2026, 21:18 UTC

Ganancias

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 jun 2026, 21:15 UTC

Ganancias

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 jun 2026, 21:13 UTC

Ganancias

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 jun 2026, 21:13 UTC

Ganancias

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 jun 2026, 21:12 UTC

Ganancias

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 jun 2026, 21:09 UTC

Ganancias

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 jun 2026, 21:03 UTC

Ganancias

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 jun 2026, 20:43 UTC

Ganancias

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 jun 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 jun 2026, 20:37 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 jun 2026, 20:35 UTC

Ganancias

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 jun 2026, 20:17 UTC

Ganancias

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 jun 2026, 20:17 UTC

Ganancias

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 jun 2026, 20:15 UTC

Ganancias

Broadcom 2Q Adj EPS $2.44 >AVGO

3 jun 2026, 20:15 UTC

Ganancias

Broadcom 2Q EPS $1.91 >AVGO

3 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

3 jun 2026, 20:15 UTC

Ganancias

Broadcom 2Q Rev $22.19B >AVGO

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

657.58% repunte

Estimación a 12 Meses

Media 20 USD 657.58%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

154 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.